Modalis Therapeutics Corporation announced that the abstract has been accepted for a presentation in the late-breaking session at the 26th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT), being held in Los Angeles CA on May 16-20, 2023. The abstracts present preclinical data from the Company's LAMA2 Congenital Muscular Dystrophy (LAMA2-CMD). Modalis presentations at ASGCT will include preclinical data demonstrating that: In LAMA-2 knockout mice (dyW disease model mice) and non-human primates (NHPs), a CRISPR-GNDM®?

based molecule (MDL-101) targeting the LAMA-1 gene introduced into a muscle-specific AAV vector raised LAMA-1 expression to levels that complement LAMA-2 function in the disease animals. This suggests that MDL-101 may have therapeutic potential in the clinic. At ASGCT, will present preclinical data from MDL-101 validating the efficacy and safety of differentiated therapeutic strategy utilizing CRISPR-GND M®?

technology for the previously difficult-to-treat LAMA2-CMD.